CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Zacks12-12

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491336030?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","is_english":true,"pubTime":"2024-12-12 23:21","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2491336030","market":"us","top_or_hot":-1,"title":"CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study","media":"Zacks","content":"<div>\n<p>Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis...</p>\n\n<a href=\"https://finance.yahoo.com/news/corts-dazucorilant-fails-meet-goal-152100886.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/corts-dazucorilant-fails-meet-goal-152100886.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis...</p>\n\n<a href=\"https://finance.yahoo.com/news/corts-dazucorilant-fails-meet-goal-152100886.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://finance.yahoo.com/news/corts-dazucorilant-fails-meet-goal-152100886.html","article_id":"2491336030","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491336030","pubTimestamp":1734016860,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis , a degenerative neurologic disorder.The double-blind, placebo-controlled DAZALS study evaluated two doses of dazucorilant  for treating patients with ALS.The study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised  in patients treated with dazucorilant versus those treated with placebo.Shares of Corcept were down in pre-market trading on Dec. 12 following the announcement of the news on Dec. 11.Year to date, shares of Corcept have rallied 85% against the industry’s decline of 4.6%.Data from the study showed that patients who were treated with dazucorilant experienced substantially more gastrointestinal upset compared to those who received placebo at the onset of treatment.Upon completing the study, patients were eligible to e","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BK4532":"文艺复兴科技持仓","SPRO":"Spero Therapeutics Inc.","CSTL":"Castle Biosciences, Inc.","IMCR":"Immunocore Holdings plc","BK4007":"制药","CORT":"Corcept医疗","BK4505":"高瓴资本持仓","BK4139":"生物科技","LU0566484027.USD":"安本美国小盘成长股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H"},"translate_title":"CORT的Dazucorilant在神经系统疾病研究中未能达到目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1,"CSTL":1,"IMCR":1,"SPRO":1},"content_text":"Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis (ALS), a degenerative neurologic disorder.\nThe double-blind, placebo-controlled DAZALS study evaluated two doses of dazucorilant (150 mg and 300 mg) for treating patients with ALS.\nThe study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients treated with dazucorilant versus those treated with placebo.\nShares of Corcept were down in pre-market trading on Dec. 12 following the announcement of the news on Dec. 11.\nYear to date, shares of Corcept have rallied 85% against the industry’s decline of 4.6%.\nImage Source: Zacks Investment Research\nMore on CORT's DAZALS Study\nData from the study showed that patients who were treated with dazucorilant experienced substantially more gastrointestinal upset compared to those who received placebo at the onset of treatment.\nUpon completing the study, patients were eligible to enter an open-label, long-term extension study that evaluated 300 mg of dazucorilant in the given patient population.\nThe open-label, long-term extension will continue and the overall survival will be assessed in March next year.\nCorcept plans to present full data from the DAZALS study at an upcoming medical conference in 2025.\nThe FDA has granted a Fast Track Designation to dazucorilant for treating ALS.\nCORT's Recent Pipeline Progress\nCorcept’s lead pipeline candidate, relacorilant, is being evaluated in phase III of the GRACE study to treat Cushing’s syndrome.\nRelacorilant is also being investigated in the phase III GRADIENT study for treating patients whose Cushing’s syndrome is caused by adrenal adenoma. While data from the GRACE study will form the basis of the new drug application (NDA) for relacorilant, data from the GRADIENT study will likely support the NDA.\nAn NDA for relacorilant in Cushing’s syndrome is likely to be submitted shortly.\nCorcept is also studying relacorilant in combination with other drugs for treating different cancer indications.\nThe phase III ROSELLA study is evaluating relacorilant in combination with nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer, with data from the same expected by 2024 end. Another study is evaluating relacorilant in combination with pembrolizumab for treating patients with adrenal cancer along with cortisol excess.\nCORT's Zacks Rank & Other Key Picks\nCorcept currently carries a Zacks Rank #2 (Buy).\nSome other top-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero Therapeutics, Inc. SPRO and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 55%.\nIMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Loss per share estimates for 2025 have narrowed from $1.54 to 79 cents during the same time. Year to date, shares of SPRO have declined 21.7%.\nSPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.\nIn the past 60 days, estimates for Castle Biosciences’ 2024 bottom line have moved from a loss of 58 cents per share to earnings of 34 cents per share. Loss per share estimates for 2025 have narrowed from $2.13 to $1.84 during the same time. Year to date, shares of CSTL have surged 36.6%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCorcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nImmunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491336030"}